Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models

作者：Qun Jiang, Azam Ghafoor, Idrees Mian, Daniel Rathkey, Anish Thomas, Christine Alewine, Manjistha Sengupta, Mark A. Ahlman, Jingli Zhang, Betsy Morrow, Seth M. Steinberg, Ira Pastan, Raffit Hassan · 发表于：Science Translational Medicine · 年份：2020 · DOI：10.1126/scitranslmed.aaz7252 · 被引用次数：44 · 研究领域：Occupational and environmental lung diseases、Cancer Research and Treatments、Neuroblastoma Research and Treatments

T cells in patients' tumors. The enhanced antitumor effects with LMB-100 plus anti-PD-1 antibody were also observed in a human peripheral blood mononuclear cell-engrafted mesothelioma mouse model and a human mesothelin-expressing syngeneic lung adenocarcinoma mouse model. LMB-100 plus pembrolizumab is now being evaluated in a prospective clinical trial for patients with mesothelioma.